Study of Lonafarnib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (Study P02530)
Status:
Terminated
Trial end date:
2004-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and efficacy of an oral Farnesyl Protein
Transferase Inhibitor (Lonafarnib/SCH 6636) as a single agent in Adult Patients With Squamous
Cell Carcinoma of the Head & Neck and will help determine if further development is
justified.